Strickland GT et al. - The evaluation of prophylactic vaccines is particularly problematic since distribution must focus upon individuals at high risk of exposure for example, intravenous drug users and health-care providers in areas with high HCV prevalence. Although there is a huge need for therapeutic vaccines, further immunological hurdles must be cleared before one becomes available.